2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an update on a four-year follow-up analysis of the NeoALTTO trial.
Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an update on a four-year follow-up analysis of the NeoALTTO trial.
In the NeoALTTO trial, patients with HER2-positive breast cancer were randomly assigned to preoperative therapy with paclitaxel and lapatinib, paclitaxel and trastuzumab, or paclitaxel plus both anti-HER2 drugs. The overall goal of the trial was to determine whether pathologic complete response (pCR) rate achieved with lapatinib plus trastuzumab translated into better overall survival or event-free survival.
Overall, the primary endpoint of the trial was met, establishing a significant connection between pCR and survival. Patients who achieved a pCR were 62% less likely to experience a cancer-related event, Piccart states. Moreover, pCR was associated with a 67% reduction in the risk of death. Taken together, these findings confirm that pCR is an acceptable surrogate endpoint, Piccart believes.